Plasmacytoid dendritic cells and their therapeutic activity in cancer

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 726-734

  Pinto, Aldo ^a   Rega, Alessia ^a   Crother, Timothy R ^b   Sorrentino, Rosalinda ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Inflammation; Plasmacytoid dendritic cells; Toll like receptors

Indexed keywords

B7 ANTIGEN; CD123 ANTIGEN; CD4 ANTIGEN; GLYCOPROTEIN P 15095; INTERFERON; INTERLEUKIN 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CELL FUNCTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; INNATE IMMUNITY; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION;

EID: 84874229724     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20171     Document Type: Article

References (79)

1. GeurtsvanKessel CH, Lambrecht BN. Division of labor between dendritic cell subsets of the lung. Mucosal Immunol 2008; 1:442-50; PMID:19079211; http://dx.doi.org/10.1038/mi.2008.39
2. Sozzani S, Vermi W, Del Prete A, Facchetti F. Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol 2010; 31:270-7; PMID:20579936; http://dx.doi.org/10.1016/j.it.2010.05.004
3. Ghosh HS, Cisse B, Bunin A, Lewis KL, Reizis B. Continuous expression of the transcription factor e2-2 maintains the cell fate of mature plasmacytoid dendritic cells. Immunity 2010; 33:905-16; PMID:21145760; http://dx.doi.org/10.1016/j.immuni.2010.11.023
4. Henri S, Vremec D, Kamath A, Waithman J, Williams S, Benoist C, et al. The dendritic cell populations of mouse lymph nodes. J Immunol 2001; 167:741-8; PMID:11441078
5. Yoneyama H, Matsuno K, Zhang Y, Nishiwaki T, Kitabatake M, Ueha S, et al. Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol 2004; 16:915-28; PMID:15159375; http://dx.doi.org/10.1093/intimm/dxh093
6. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5:1219-26; PMID:15549123; http://dx.doi.org/10.1038/ni1141
7. Sorrentino R, Morello S, Pinto A. Role of plasmacytoid dendritic cells in lung-associated inflammation. Recent Pat Inflamm Allergy Drug Discov 2010; 4:138-43; PMID:20394583; http://dx.doi.org/10.2174/187221310791163062
8. Yoneyama H, Matsuno K, Zhang Y, Nishiwaki T, Kitabatake M, Ueha S, et al. Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol 2004; 16:915-28; PMID:15159375; http://dx.doi.org/10.1093/intimm/dxh093
9. Penna G, Sozzani S, Adorini L. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 2001; 167:1862-6; PMID:11489962
10. Vanbervliet B, Bendriss-Vermare N, Massacrier C, Homey B, de Bouteiller O, Brière F, et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med 2003; 198:823-30; PMID:12953097; http://dx.doi.org/10.1084/jem.20020437
11. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 2010; 1183:89-103; PMID:20146710; http://dx.doi.org/10.1111/j.1749-6632.2009.05152.x
12. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7:1339-46; PMID:11726975; http://dx.doi.org/10.1038/nm1201-1339
13. Penna G, Volcano M, Sozzani S, Adorini L. Differential migration Behavior and chemokine production by myeloid and plasmacytoid Dendridic cells. Hum Immunol 2002; 36:1164-71; http://dx.doi.org/10.1016/S0198-8859(02)00755-3
14. Xu H, Zhang GX, Ciric B, Rostami A. IDO: a doubleedged sword for T(H)1/T(H)2 regulation. Immunol Lett 2008; 121:1-6; PMID:18824197; http://dx.doi.org/10.1016/j.imlet.2008.08.008
15. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-31; PMID:14976261; http://dx.doi.org/10.1126/science.1093616
16. Gilliet M, Cao W, Liu Y-J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8:594-606; PMID: 18641647; http://dx.doi.org/10.1038/nri2358
17. Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D. Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol 2010; 31:391-7; PMID:20832362; http://dx.doi.org/10.1016/j.it.2010.07.004
18. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23:275-306; PMID:15771572; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115633
19. Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med 2011; 208:2367-74; PMID:22084408; http://dx.doi.org/10.1084/jem.20110654
20. Blasius AL, Colonna M. Sampling and signaling in plasmacytoid dendritic cells: the potential roles of Siglec-H. Trends Immunol 2006; 27:255-60; PMID: 16679063; http://dx.doi.org/10.1016/j.it.2006.04.005
21. Kassner N, Krueger M, Yagita H, Dzionek A, Hutloff A, Kroczek R, et al. Cutting edge: Plasmacytoid dendritic cells induce IL-10 production in T cells via the Delta-like-4/Notch axis. J Immunol 2010; 184: 550-4; PMID:20008296; http://dx.doi.org/10.4049/jimmunol.0903152
22. Boonstra A, Rajsbaum R, Holman M, Marques R, Asselin-Paturel C, Pereira JP, et al. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88-and TRIFdependent TLR signals, and TLR-independent signals. J Immunol 2006; 177:7551-8; PMID:17114424
23. Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012; 122:575-85; PMID:22251703; http://dx.doi.org/10.1172/JCI61034
24. Kalb ML, Glaser A, Stary G, Koszik F, Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod-and IFN-α-mediated antitumor reactivity. J Immunol 2012; 188:1583-91; PMID:22231699; http://dx.doi.org/10.4049/jimmunol.1102437
25. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, et al. BDCA-2 a novel plasmacytoid cell-specific tipe II C-type of lectin, mediates antigen capture and is a potent inhibitor of interferon a/B induction. J Exp Med 2001; 194:1823-34; PMID: 11748283; http://dx.doi.org/10.1084/jem.194.12.1823
26. Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M. Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual. Immunity 2010; 33:955-66; PMID: 21130004; http://dx.doi.org/10.1016/j.immuni.2010.11.020
27. Takagi H, Fukaya T, Eizumi K, Sato Y, Sato K, Shibazaki A, et al. Plasmacytoid dendritic cells are crucial for the initiation of inflammation and T cell immunity in vivo. Immunity 2011; 35:958-71; PMID: 22177923; http://dx.doi.org/10.1016/j.immuni.2011.10.014
28. Asselin-Paturel C, Brizard G, Pin JJ, Brière F, Trinchieri G. Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol 2003; 171: 6466-77; PMID:14662846
29. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, Colonna M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 2006; 177: 3260-5; PMID:16920966
30. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT, et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004; 21:107-19; PMID:15345224; http://dx.doi.org/10.1016/j.immuni.2004.06.007
31. Asselin-Paturel C, Trinchieri G. Production of type I interferons: plasmacytoid dendritic cells and beyond. J Exp Med 2005; 202:461-5; PMID:16103406; http://dx.doi.org/10.1084/jem.20051395
32. Shaw J, Wang YH, Ito T, Arima K, Liu YJ. Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. Blood 2010; 115:3051-7; PMID:20139096; http://dx.doi.org/10.1182/blood-2009-08-239145
33. Asselin-Paturel C, Boonstra A, Dalod M, Durand I, Yessaad N, Dezutter-Dambuyant C, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001; 2:1144-50; PMID:11713464; http://dx.doi.org/10.1038/ni736
34. Björck P. Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocytemacrophage colony-stimulating factor-treated mice. Blood 2001; 98:3520-6; PMID:11739152; http://dx.doi.org/10.1182/blood.V98.13.3520
35. Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008; 29:352-61; PMID:18799143; http://dx.doi.org/10.1016/j.immuni.2008.09.002
36. Wilson NS, Villadangos JA. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol 2005; 86:241-305; PMID: 15705424; http://dx.doi.org/10.1016/S0065-2776(04)86007-3
37. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 2001; 194:1823-34; PMID:11748283; http://dx.doi.org/10.1084/jem.194.12.1823
38. Villadangos JA, Schnorrer P, Wilson NS. Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunol Rev 2005; 207:191-205; PMID:16181337; http://dx.doi.org/10.1111/j.0105-2896.2005.00317.x
39. Jaehn PS, Zaenker KS, Schmitz J, Dzionek A. Functional dichotomy of plasmacytoid dendritic cells: antigen-specific activation of T cells versus production of type I interferon. Eur J Immunol 2008; 38:1822-32; PMID:18581320; http://dx.doi.org/10.1002/eji.200737552
40. Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ, et al. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood 2008; 111:4245-53; PMID:18258799; http://dx.doi.org/10.1182/blood-2007-03-081398
41. Loschko J, Heink S, Hackl D, Dudziak D, Reindl W, Korn T, et al. Antigen targeting to plasmacytoid dendritic cells via Siglec-H inhibits Th cell-dependent autoimmunity. J Immunol 2011; 187:6346-56; PMID: 22079988; http://dx.doi.org/10.4049/jimmunol.1102307
42. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117:2570-82; PMID:17710230; http://dx.doi.org/10.1172/JCI31911
43. Kassner N, Krueger M, Yagita H, Dzionek A, Hutloff A, Kroczek R, et al. Cutting edge: Plasmacytoid dendritic cells induce IL-10 production in T cells via the Delta-like-4/Notch axis. J Immunol 2010; 184: 550-4; PMID:20008296; http://dx.doi.org/10.4049/jimmunol.0903152
44. Lee SM, Lee YS, Choi JH, Park SG, Choi IW, Joo YD, et al. Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion. Immunol Lett 2010; 132:53-60; PMID:20570696; http://dx.doi.org/10.1016/j.imlet.2010.05.008
45. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005; 22:633-42; PMID:15894280; http://dx.doi.org/10.1016/j.immuni.2005.03.013
46. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117:2570-82; PMID:17710230; http://dx.doi.org/10.1172/JCI31911
47. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27:3889-900; PMID:18317452; http://dx.doi.org/10.1038/onc.2008.35
48. Sorrentino R, Gray P, Chen S, Shimada K, Crother TR, Arditi M. Plasmacytoid Dendritic Cells Prevent Cigarette Smoke and Chlamydophila pneumoniae- induced Th2 Inflammatory Responses. Am J Respir Cell Mol Biol 2010; 43:422-31; PMID:19901344; http://dx.doi.org/10.1165/rcmb.2009-0224OC
49. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176:6752-61; PMID:16709834
50. Tokita D, Mazariegos GV, Zahorchak AF, Chien N, Abe M, Raimondi G, et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 2008; 85:369-77; PMID:18301333; http://dx.doi.org/10.1097/TP.0b013e3181612ded
51. Puccetti P, Fallarino F. Generation of T cell regulatory activity by plasmacytoid dendritic cells and tryptophan catabolism. Blood Cells Mol Dis 2008; 40:101-5; PMID:17881253; http://dx.doi.org/10.1016/j.bcmd.2007.06.026
52. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-74; PMID:14502282; http://dx.doi.org/10.1038/nm934
53. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008; 222:206-21; PMID: 18364004; http://dx.doi.org/10.1111/j.1600-065X.2008.00610.x
54. Vermi W, Soncini M, Melocchi L, Sozzani S, Facchetti F. Plasmacytoid dendritic cells and cancer. J Leukoc Biol 2011; 90:681-90; PMID:21730085; http://dx.doi.org/10.1189/jlb.0411190
55. Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, et al. Plasmacytoid dendritic cells induce NK celldependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008; 118:1165-75; PMID:18259609
56. Erreni M, Mantovani A, Allavena P. Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron 2011; 4:141-54; PMID: 21909876; http://dx.doi.org/10.1007/s12307-010-0052-5
57. Sorrentino R, Morello S, Luciano A, Crother TR, Maiolino P, Bonavita E, et al. Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma. J Immunol 2010; 185:4641-50; PMID:20855872; http://dx.doi.org/10.4049/jimmunol.1000881
58. Bekeredjian-Ding I, Schäfer M, Hartmann E, Pries R, Parcina M, Schneider P, et al. Tumour-derived prostaglandin E and transforming growth factor-β synergize to inhibit plasmacytoid dendritic cell-derived interferon-α. Immunology 2009; 128:439-50; PMID: 20067543; http://dx.doi.org/10.1111/j.1365-2567.2009.03134.x
59. Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumorderived interleukin-8 and relation to clinical outcome. Am J Pathol 1998; 152:83-92; PMID:9422526
60. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996; 56:5499-505; PMID:8968107
61. Kurtz J, Raval F, Vallot C, Der J, Sykes M. CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance. Blood 2009; 113: 3475-84; PMID:19179471; http://dx.doi.org/10.1182/blood-2008-01-133736
62. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011; 12:870-8; PMID:21804557; http://dx.doi.org/10.1038/ni.2077
63. Tsukamoto N, Okada S, Onami Y, Sasaki Y, Umezawa K, Kawakami Y. Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. Clin Cancer Res 2009; 15:5733-43; PMID:19723650; http://dx.doi.org/10.1158/1078-0432.CCR-09-0171
64. de Heer HJ, Hammad H, Soullié T, Hijdra D, Vos N, Willart MA, et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004; 200:89-98; PMID:15238608; http://dx.doi.org/10.1084/jem.20040035
65. Smit JJ, Lindell DM, Boon L, Kool M, Lambrecht BN, Lukacs NW. The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS One 2008; 3: e1720; PMID:18320041; http://dx.doi.org/10.1371/journal.pone.0001720
66. Bratke K, Klein C, Kuepper M, Lommatzsch M, Virchow JC. Differential development of plasmacytoid dendritic cells in Th1-and Th2-like cytokine milieus. Allergy 2011; 66:386-95; PMID:21039603; http://dx.doi.org/10.1111/j.1398-9995.2010.02497.x
67. Battaglia M, Gianfrani C, Gregori S, Roncarolo MG. IL-10-producing T regulatory type 1 cells and oral tolerance. Ann N Y Acad Sci 2004; 1029:142-53; PMID:15681753; http://dx.doi.org/10.1196/annals. 1309.031
68. Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, et al. Dendritic cell vaccines in melanoma: from promise to proof?. Crit Rev Oncol Hematol 2008; 66:118-34; PMID:18262431; http://dx.doi.org/10.1016/j.critrevonc.2007.12.007
69. Hurtado P, Peh CA. LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J Immunol 2010; 184: 1425-35; PMID:20042575; http://dx.doi.org/10.4049/jimmunol.0902305
70. Chuang CM, Monie A, Wu A, Mao CP, Hung CF. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther 2009; 20:303-13; PMID:19272013; http://dx.doi.org/10.1089/hum.2008.124
71. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66:1-9; PMID:17913510; http://dx.doi.org/10.1016/j.critrevonc.2007.07.004
72. Schlecht G, Garcia S, Escriou N, Freitas AA, Leclerc C, Dadaglio G. Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. Blood 2004; 104:1808-15; PMID:15166034; http://dx.doi.org/10.1182/blood-2004-02-0426
73. Aspord C, Charles J, Leccia MT, Laurin D, Richard MJ, Chaperot L, et al. A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells. PLoS One 2010; 5:e10458; PMID:20454561; http://dx.doi.org/10.1371/journal.pone.0010458
74. Lou Y. liu C, Kim GJ, Liu Y-J, Hwu P., Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells ie induction of antigen-specific antitumour immune responses. J Immunol 2007; 178: 1534-41; PMID:17237402
75. Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M. Intratumor CpGoligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 2003; 171:3941-6; PMID:14530311
76. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.Muñoz L, Nomdedéu JF, López O, Carnicer MJ, Bellido M, Aventín A, Brunet S. Sierra J. Haematologica 2001; 86:1261-9.
77. Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, Cortesini R, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 2003; 11:245-58; PMID:12967778; http://dx.doi.org/10.1016/S0966-3274(03)00058-3
78. Cho M, Ishida K, Chen J, Ohkawa J, Chen W, Namiki S, et al. SAGE library screening reveals ILT7 as a specific plasmacytoid dendritic cell marker that regulates type I IFN production. Int Immunol 2008; 20:155-64; PMID:18048391; http://dx.doi.org/10.1093/intimm/dxm127
79. Sadhu C, Ting HJ, Lipsky B, Hensley K, Garcia-Martinez LF, Simon SI, et al. CD11c/ CD18: novel ligands and a role in delayed-type hypersensitivity. J Leukoc Biol 2007; 81:1395-403; PMID:17389580; http://dx.doi.org/10.1189/jlb.1106680